The announcement on 6 April stated that Veyonda appears to be the first drug that blocks STING in the clinic (my emphasis). This is different from saying Veyonda is the first drug in the clinic that appears to block STING. Taken literally, this means that Veyonda appears to have blocked overactive STING in NOXCOVID patients.
The analysis of NOXCOVID blood plasma should show the before-and-after levels of a wide range of cytokines, and biomarkers of Inflammation.
When results are released, the world will find out:
Positive results could be a company-maker for Noxopharm.
- Whether NOXCOVID patients responded positively to Veyonda
- Whether Veyonda is able to inhibit STING when it gets out of control (but have no effect when STING acts normally)
- Whether Veyonda could be an effective, self-administered treatment for the 10 million people each year who face death after deteriorating from moderate to serious Septic Shock.
Add to My Watchlist
What is My Watchlist?
